PDRN vs Polynucleotides: Understanding the Key Differences

Introduction

The terms PDRN and polynucleotides (PN) are frequently used interchangeably in aesthetic medicine marketing, creating significant confusion among both practitioners and patients. While both are DNA-derived biopolymers that share the same fundamental mechanism of action through adenosine A2A receptor activation, they represent distinct product categories with meaningful differences in molecular characteristics, pharmacokinetics, and clinical behavior.

Molecular Weight: The Defining Distinction

The primary difference between PDRN and PN lies in molecular weight. PDRN (Polydeoxyribonucleotide) consists of DNA fragments with molecular weights ranging from 50 to 1500 kilodaltons (kDa). These shorter chains are produced through controlled enzymatic or mechanical fragmentation of larger DNA molecules.

Polynucleotides (PN), by contrast, retain molecular weights above 1500 kDa and can extend to several thousand kDa. These longer chains are closer in size to native genomic DNA and undergo less fragmentation during the extraction process.

This difference in chain length has direct consequences for product behavior in tissue. Shorter PDRN chains diffuse more readily through the extracellular matrix, achieving broader tissue distribution from each injection point. Longer PN chains, due to their greater hydrodynamic volume, remain more localized at the injection site and exhibit viscoelastic (gel-like) properties that PDRN solutions lack.

Source Organisms

Both PDRN and PN are extracted from fish gonads, but the species used may differ by manufacturer:

• PDRN products (e.g., Rejuran, Plinest) commonly derive from Oncorhynchus keta (chum salmon) or Oncorhynchus mykiss (rainbow trout).
• PN products (e.g., Nucleofill, Pluryal Silk) are often extracted from Oncorhynchus mykiss (rainbow trout), particularly by Italian manufacturers.

The source organism affects the base composition and sequence heterogeneity of the extracted material, though both yield products with comparable biological activity at the receptor level.

Mechanism of Action: Shared Core, Different Kinetics

Both PDRN and PN activate the adenosine A2A receptor on fibroblasts and endothelial cells, triggering cAMP-dependent signaling that promotes cell proliferation, collagen synthesis, and anti-inflammatory responses. Both also contribute nucleotide building blocks to the salvage pathway upon degradation.

However, the pharmacokinetic profiles differ. PDRN's smaller fragments are degraded more quickly by tissue nucleases, providing a burst of nucleotide substrates and relatively rapid A2A stimulation. PN's larger chains degrade more slowly, offering sustained receptor activation over a longer period. Additionally, intact high-MW polynucleotide chains exhibit free radical scavenging activity proportional to chain length, giving PN products an enhanced antioxidant effect.

Clinical Implications

In practice, these molecular differences translate to complementary clinical roles:

• PDRN is preferred for broad-area skin rejuvenation (nappage technique), under-eye treatments, and applications where rapid diffusion and tissue penetration are desired.
• PN is favored when bioscaffolding, mild volumization, or sustained release is beneficial — such as in deeper dermal biorestructuring or treatment of moderately volume-depleted areas.

Conclusion

PDRN and PN are siblings, not twins. Understanding their molecular differences allows practitioners to select the optimal product for each clinical scenario, and helps patients set realistic expectations for their treatments. As the regenerative aesthetics field matures, precision in terminology will become increasingly important.